Patent · US Active

Recombinant rhabdovirus encoding for CCL21

US11707495B2 · kind B2 · utility

0Cited by

1References

34Claims

0Family size

Assignees

Boehringer Ingelheim International GmbH · DE
ViraTherapeutics GmbH · AT

Inventors

Philipp Mueller · Waldshut-Tiengen, DE
Klaus Erb · Mittelbiberach, DE
Patrik ERLMANN · Neu Götzens, AT
Tobias Friederike NOLDEN · Birgitz, AT
John Park · Warthausen, DE
Guido Wollmann · Innsbruck, AT

Key dates

Filing date	Jan 24, 2020
Grant date	Jul 25, 2023
Priority date	—
Expiry date	Jul 31, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/20245
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.